Showing results (61-70 of 115) with videos related to
Sort By:
Pageof 12
Cancer Medicine|September 18, 2015
Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependenceEsther N Oliva, Michael Lauseker, Maria Antonietta Aloe Spiriti, et al.Aging|December 14, 2021
IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosisLucia Longhitano, Daniele Tibullo, Nunzio Vicario, et al.Leukemia|May 28, 2025
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyureaFrancesca Palandri, Massimo Breccia, Elena M Elli, et al.Experimental Hematology|November 12, 2013
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemiaRossana Maffei, Stefania Fiorcari, Jenny Bulgarelli, et al.Antioxidants (Basel, Switzerland)|April 27, 2024
Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis PatientsRenata Mangione, Cesarina Giallongo, Andrea Duminuco, et al.International Journal of Molecular Sciences|February 3, 2019
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron OverloadGiuseppina Camiolo, Daniele Tibullo, Cesarina Giallongo, et al.Current Oncology (Toronto, Ont.)|November 24, 2023
Multiple Myeloma in 2023 Ways: From Trials to Real LifeManlio Fazio, Vittorio Del Fabro, Nunziatina Laura Parrinello, et al.Haematologica|January 18, 2015
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL studyDavide Rossi, Alessio Bruscaggin, Piera La Cava, et al.Leukemia Research|November 19, 2013
Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter studyJudith Neukirchen, Michael Lauseker, Sabine Blum, et al.Pharmaceuticals (Basel, Switzerland)|July 27, 2024
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid LeukemiaMariarita Spampinato, Tatiana Zuppelli, Ilaria Dulcamare, et al.Pageof 12